Clinical Trial


A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa


Brief description

The primary purpose of this study is to assess the preventive vaccine efficacy (VE), safety and tolerability of a heterologous prime/boost regimen utilizing Ad26.Mos4.HIV and aluminum-phosphate adjuvanted Clade C gp 140 for the prevention of Human Immuno Virus (HIV) infection in HIV-seronegative women residing in sub-Saharan Africa from confirmed HIV-1 infections diagnosed between the Month 7 and Month 24 visits.

Keywords

  •   HIV-1

Sponsored By

Janssen Vaccines & Prevention B.V.

Unique Study ID

NCT03060629

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

University of Bern
Lilongwe, Malawi
Distance from Current Trial is 0 miles

No Investigator Listed

UNC Lineberger Comprehensive Cancer Center
Lilongwe, Malawi
Distance from Current Trial is 0 miles

No Investigator Listed

University of Colorado, Denver
Lilongwe, Malawi
Distance from Current Trial is 0 miles
View All